A downtrend has been apparent in Sarepta Therapeutics (SRPT) lately with too much selling pressure. The stock has declined 10.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicat ...

Sarepta Therapeutics, Inc. (SRPT) posted earnings of 7 cents per share in second-quarter 2024, beating the Zacks Consensus Estimate of breakeven earnings. In the year-ago period, the company posted a loss of 27 cents. The loss included depreciation and amortization expenses and stock-based compensation expenses. Adjusted earnings per share in the quarter stood at 44 cents against the year-ago period's adjusted loss of $1.01 per share. Sarepta recorded total revenues of $362.9 million, up 39% year over year. ...

For the quarter ended June 2024, Sarepta Therapeutics (SRPT) reported revenue of $362.93 million, up 38.9% over the same period last year. EPS came in at $0.07, compared to -$0.27 in the year-ago quarter. ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations & Corporate Communications Doug Ingram - President & Chief Executive Officer Dallan Murray - Executive Vice President & Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer & Head of Research & Development Ian Estepan - Executive Vice President & Chief Financial Officer Conference Call Partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol Name of exchange on which registered Common Stock, $0.0001 par value per share SRPT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

The mean estimate comprises 17 short-term price targets with a standard deviation of $22. While the lowest estimate of $165 indicates a 14.8% increase from the current price level, the most optimistic analyst expects the stock to surge 63.4% to reach $235. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. Sarepta Therapeutics (SRPT) closed the last trading session at ...

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Sarepta Therapeutics ...

Sarepta developed Elevidys in collaboration with Roche (RHHBY) . Both companies entered into a licensing agreement in 2019 to develop and market Elevidys. Per the agreement, Sarepta is responsible for marketing the therapy in the United States, while Roche is responsible for marketing the gene therapy outside the country. Sarepta is also eligible to receive collaboration revenues on the ex-U.S. sales made by Roche. This latest approval significantly expands the company's target market as it can increase its ...

Sarepta Therapeutics (SRPT) shares ended the last trading session 30.1% higher at $160.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.9% loss over the past four weeks. The label expansion is mainly supported by data from the phase III EMBARK study, announced last October. Though the study failed to achieve its primary endpoint, it achieved statistical significance on all pre-specified key secondary endpoints ...

Shares of Sarepta (SRPT) rose nearly 34% in after-market trading on Thursday after it announced that the FDA approved the expanded use of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Elevidys is now approved to treat all DMD patients aged four years and older. While the FDA granted traditional approval for the therapy to treat ambulatory DMD patients (those who can still walk), it has granted accelerated approval for non-ambulatory patients. The label expansion is mainly supported by data fr ...